Cancer therapeutics targeting DR4/DR5 including the first generation of rsTRAIL and anti-DR4/DR5 agonistic monoclonal antibodies have disappointed in the clinical trials 16, 41. This evidence concerns the gene TNFRSF10A and cancer.